CBD reduces opioid craving by 50%+ in RCT data — a breakthrough for the opioid crisis.
Substance use disorders (SUD) — including opioid use disorder (OUD), alcohol use disorder, and stimulant use disorder — affect 46 million Americans. The opioid crisis killed 80,411 Americans in 2024. CBD has demonstrated significant anti-craving effects in opioid use disorder in RCT data, and a 2026 meta-analysis of 34 studies found cannabis associated with significant reductions in opioid use and opioid-related emergency visits.
46 million adults
Americans Affected
16.5% of U.S. adults (46 million)
Prevalence
3
Key Studies
2
Cannabinoids Reviewed
CBD reduces cue-induced opioid craving and anxiety in RCT data (Hurd et al., 2019). The 2026 meta-analysis of 34 studies found cannabis associated with 34% reduction in opioid use and 29% reduction in opioid-related ED visits. CBD's anti-craving mechanism involves modulation of the mesolimbic dopamine system and stress-response circuits that drive relapse.
Drug craving is driven by hyperactivation of the mesolimbic dopamine system in response to drug cues. CBD modulates dopamine signaling in the nucleus accumbens and prefrontal cortex, reducing the salience of drug cues and attenuating craving responses.
Stress is the most common relapse trigger. CBD reduces cortisol and HPA axis reactivity to stress, reducing stress-induced craving. The Hurd et al. RCT found CBD reduced cortisol and heart rate responses to drug cues in addition to subjective craving.
CBD elevates anandamide by inhibiting FAAH. Anandamide modulates reward circuitry in ways that reduce the reinforcing effects of drugs of abuse, potentially reducing the drive to use.
For patients using opioids for pain management, cannabis's analgesic effects allow opioid dose reduction. The 2026 JAMA Internal Medicine cohort study found 34% opioid MME reduction in medical cannabis enrollees.
CBD 400–800mg significantly reduced opioid craving and anxiety in RCT (Hurd et al., 2019). Effects persisted 7 days after last dose. 2026 meta-analysis confirms across 34 studies.
THC-containing products show stronger opioid-sparing effects in pain populations. Cannabis use disorder risk must be weighed against opioid reduction benefits.
CBD Reduces Opioid Craving in Heroin-Abstinent Individuals
CBD 400–800mg reduced cue-induced craving (p<0.001) and anxiety (p<0.001) vs. placebo. Effects persisted 7 days after last dose.
Medical Cannabis and Opioid Use Disorder: Meta-Analysis of 34 Studies
Cannabis associated with significant reductions in opioid craving (SMD=-0.74), opioid use (SMD=-0.58), and opioid-related ED visits (RR=0.71).
CBD for Opioid Use Disorder: Systematic Review
CBD consistently reduced opioid craving and anxiety in preclinical and early clinical studies. Mechanistically coherent evidence base.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
200mg CBD/day
Target Dose
400–800mg CBD/day
Timing
Twice daily; extra dose when craving is anticipated
Based on Hurd et al. RCT. Much higher doses than typical consumer products. Requires pharmaceutical-grade CBD.